Recently, an angiotensin receptor-neprilysin inhibitor (ARNi) was approved as a first-in-class drug for the treatment of HF in both Europe and the U.S., representing a new milestone in pharmaceutical treatment for HF (2). Here, MME is linked to hydrops fetalis.